EUCTR2021-006511-29-NO进行中（未招募）1 期
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS) - CARDINALS
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 258
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Males or females aged between 18 and 80 years at the time of the initial Screening Visit
- •2. ALS with preserved function, defined as:
- •a. Onset of the first symptom leading to the diagnosis of ALS =24 months at the time of the initial Screening Visit
- •b. Revised El Escorial criteria of either:
- •(i) Clinically definite ALS
- •(ii) Clinically probable ALS
- •3. A total ALSFRS-R score of at least 34 at the start of the Screening Period
- •4. No significant respiratory compromise as evidenced by slow vital capacity =60% at the start of the Screening Period
- •5. All chronic concomitant medications (both prescription and over the counter [OTC]) and non pharmacologic therapy regimens, excluding standard-of-care therapy riluzole, edaravone, or sodium phenylbutyrate/taurursodiol, and non pharmacologic therapy regimens should be stable and unchanged from at least 14 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study
- •6. Female subjects must have a negative breast cancer imaging screening status (not considered clinically abnormal and/or requiring further evaluation/treatment) within 6 months prior to the Screening Visit or during the Screening Period.
- •7. Standard-of-care therapy for the treatment of ALS (riluzole, edaravone, or sodium phenylbutyrate/taurursodiol) should be stable and unchanged from 30 (-3) days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 248
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Females who are pregnant or nursing or plan to become pregnant during the study
- •2. Subjects with clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular/ischemic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
- •3. Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator or the medical monitor, would interfere with the subject’s ability to participate in the study or increase the risk of participation for that subject
- •4. Current participation in any other investigational study with an investigational product or participation within 30 days prior to the start of the Screening Period or 5 half-lives of the previously taken investigational drug, whichever is longer
- •5. Subject has previously received PTC857
- •6. Subjects is receiving a combination of edaravone and sodium phenylbutyrate/taurursodiol treatment, where applicable, within 30 (-3) days prior to the start of the Screening Period
- •7. For female subjects, any past medical history of breast cancer, regardless of remission status, or any first degree relative with history of breast cancer
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate whether a potential new drug is an effective and safe way to make damaged kidneys work better in patients with type II diabetesEUCTR2010-021358-20-GBPfizer Inc. 235 east 42nd Street, New York, NY 10017256
进行中（未招募）
1 期
A Phase 2 study of PTC857 in patients with Amyotrophic Lateral SclerosisEUCTR2021-006511-29-PLPTC Therapeutics, Inc.258
进行中（未招募）
1 期
A clinical study to evaluate the effects and safety of three doses of Tofacitinib (a drug that is being investigated for the treatment of rheumatoid arthritis) in subjects with active Ankylosing spondylitis (AS) (a form of Arthritis)Ankylosing Spondylitis (AS)MedDRA version: 17.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-005689-39-SKPfizer Inc. 235 East 42nd Street, New York, 10017208
进行中（未招募）
1 期
A STUDY IN CAT-ALLERGIC PATIENTS WITH ASTHMA TO EVALUATE THE EFFICACY OF REGN1908-1909EUCTR2018-002477-22-FRRegeneron Pharmaceuticals, Inc.60
进行中（未招募）
1 期
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSISEUCTR2018-004431-79-GBCelgene Corporation300